METASTATIC PANCREATIC ADENOCARCINOMA
Clinical trials for METASTATIC PANCREATIC ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC PANCREATIC ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC PANCREATIC ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to starve pancreatic tumors
Disease control OngoingThis early-phase trial tests a combination of two drugs—calaspargase pegol-mknl and cobimetinib—in about 15 people with advanced pancreatic cancer that has spread. The goal is to find the safest dose and see how well the drugs work together to starve cancer cells by cutting off a…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE1 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated May 17, 2026 03:30 UTC
-
New hope for pancreatic cancer: experimental drug DZ-002 enters phase 2 trial
Disease control ENROLLING_BY_INVITATIONThis study tests a new drug called DZ-002 in adults with metastatic pancreatic cancer that has not spread through families. Participants have already completed at least 4 months of standard chemotherapy and their disease is stable. The drug is given weekly through an IV in 4-week…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Hoag Memorial Hospital Presbyterian • Aim: Disease control
Last updated May 17, 2026 03:26 UTC
-
New combo shows promise in tough pancreatic cancer battle
Disease control OngoingThis study tests whether adding the experimental drug veliparib to standard chemotherapy (FOLFIRI) helps people with metastatic pancreatic cancer live longer. About 123 participants whose cancer returned after initial treatment will be randomly assigned to receive either FOLFIRI …
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 03:24 UTC
-
New combo therapy aims to stall pancreatic cancer in BRCA patients
Disease control OngoingThis study tests whether adding pembrolizumab (an immunotherapy) to olaparib (a targeted therapy) works better than olaparib alone for people with metastatic pancreatic cancer who have inherited BRCA1 or BRCA2 mutations. About 88 participants will receive either the combination o…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 03:23 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tests a new drug called sEphB4-HSA alongside standard chemotherapy in people with advanced or metastatic solid tumors (like head and neck, pancreatic, lung, and gallbladder cancers). The main goals are to find the best dose and check for side effects. About…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New hope for pancreatic cancer: targeted therapy plus chemo shows promise
Disease control OngoingThis study tests a new drug called zolbetuximab, which targets a protein (CLDN18.2) found in most pancreatic cancers. It is given along with standard chemotherapy to people whose pancreatic cancer has spread. The goal is to see if adding zolbetuximab helps people live longer and …
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New hope for pancreatic cancer: drug combo aims to extend remission
Disease control OngoingThis study tests whether adding ivaltinostat to standard capecitabine can help control metastatic pancreatic cancer longer after initial chemotherapy. About 70 adults whose cancer hasn't worsened on FOLFIRINOX will receive either the combination or capecitabine alone. The goal is…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: CG Pharmaceuticals, Inc • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
New drug combo targets tough cancers: hope for liver, pancreas, and bile duct tumors
Disease control OngoingThis early-phase study tests a combination of two drugs, guadecitabine and durvalumab, in people with advanced liver, pancreatic, bile duct, or gallbladder cancer that has spread. The main goals are to find the safest dose and see if the drugs can shrink tumors. About 55 particip…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated May 12, 2026 13:42 UTC
-
Which chemo combo works best for older pancreatic cancer patients?
Disease control OngoingThis study tests two different chemotherapy combinations in older adults (age 70+) whose pancreatic cancer has spread. The goal is to see which treatment helps people live longer. Both treatments are already used for pancreatic cancer, but this trial focuses specifically on older…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated May 11, 2026 20:52 UTC
-
New drug cocktail targets Hard-to-Treat pancreatic cancer
Disease control OngoingThis early-phase study tested a combination of three drugs (gemcitabine, dasatinib, and erlotinib) in 19 patients with advanced pancreatic cancer that had spread or could not be removed by surgery. The main goal was to find the safest dose and check for side effects. Researchers …
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:49 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control OngoingThis study tests a combination of two drugs, cediranib and olaparib, in people with advanced or inoperable solid tumors, including certain breast, lung, and pancreatic cancers. The goal is to see if the combo can shrink tumors or slow their growth by blocking enzymes that cancer …
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 08, 2026 12:04 UTC
-
Can digestive enzymes help fight weight loss in pancreatic cancer?
Disease control OngoingThis study tests whether a pancreatic enzyme replacement called pancrelipase can help maintain or improve body weight in people with metastatic pancreatic cancer. About 17 participants will receive either the enzyme or a placebo, and researchers will measure changes in body mass …
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 06, 2026 16:15 UTC
-
New hope for pancreatic cancer: targeted drug plus chemo shows promise in early trial
Disease control OngoingThis early-stage study tests a new drug called zolbetuximab combined with standard chemotherapy for people with advanced pancreatic cancer that has spread. The drug targets a protein on cancer cells to help the immune system attack them. The main goal is to see if the combination…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Apr 26, 2026 19:35 UTC